You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-Enriched

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Nanjing (Pyrotinib, trastuzumab, abraxane)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib, trastuzumab, abraxane
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Dec 20, 2022

Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Houston, Texas
    Houston Methodist Cancer Center
Aug 5, 2022

HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study Trial (Herzuma)

Not yet recruiting
  • HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
  • (no location specified)
Apr 25, 2021

Breast Cancer Trial in Portugal, Spain (Neratinib + endocrine therapy)

Recruiting
  • Breast Cancer
  • Neratinib + endocrine therapy
  • Lisboa, Portugal
  • +14 more
Jul 23, 2021

Metastatic Breast Cancer Trial in Portugal, Spain (Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR

Recruiting
  • Metastatic Breast Cancer
  • Ribociclib + Letrozole OR Fulvestrant
  • +2 more
  • Creixomil, Portugal
  • +44 more
Apr 1, 2022

Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab deruxtecan
  • +9 more
  • Malmö, Sweden
  • +6 more
Jun 8, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)

    Not yet recruiting
    • 18F-HER2 PET
    • 18F-HER2 PET
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of med
    Aug 2, 2023

    HER2 Expression and Clinical Pathological Characteristics in

    Recruiting
    • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
    • Collect HER2 expression in prostate cancer patients
    • Jinan, Shandong, China
      Qilu hospital
    Nov 17, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      Stroke Trial in Wishaw (Technology enriched stroke rehabilitation)

      Not yet recruiting
      • Stroke
      • Technology enriched stroke rehabilitation
      • Wishaw, Lanarkshire, United Kingdom
        University Hospital Wishaw
      Jul 31, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      HER2-positive Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

      Not yet recruiting
      • Solid Tumor
      • Intravenous infusion anti-HER2-CAR-T cell
      • Shenyang, Liaoning, China
        Phase I Clinical Trials Center Of The First Hospital of China Me
      Oct 30, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

      Recruiting
      • HER2-positive Gastric Cancer
      • Immunotherapy
      • Disitamab Vedotin combined with fruquintinib and Tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 8, 2023

      Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Cessation of anti-HER2 treatment
      • Boston, Massachusetts
      • +1 more
      Feb 9, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      Diabetic Retinopathy Trial (Docosahexaenoic Acid and Lutein Enriched Eggs, Regular Eggs)

      Recruiting
      • Diabetic Retinopathy
      • Type 2 Diabetes
      • Docosahexaenoic Acid and Lutein Enriched Eggs
      • Regular Eggs
      • Winnipeg, Manitoba, Canada
        Asper Clinical Research Institute
      Nov 1, 2022

      Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte

      Recruiting
      • Malignant Neoplasm
      • +4 more
      • Chimeric Antigen Receptor T-Cell Therapy
      • Duarte, California
        City of Hope Medical Center
      Sep 14, 2022

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023

      HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

      Not yet recruiting
      • HER2 Low Breast Carcinoma
      • SHR-A1811 for injection
      • (no location specified)
      Jun 12, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023